Harbor Capital Advisors Inc. Buys 46,262 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Harbor Capital Advisors Inc. increased its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 56.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 128,913 shares of the medical equipment provider’s stock after acquiring an additional 46,262 shares during the period. Lantheus comprises approximately 0.6% of Harbor Capital Advisors Inc.’s investment portfolio, making the stock its 24th largest holding. Harbor Capital Advisors Inc. owned 0.19% of Lantheus worth $14,148,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of LNTH. Farallon Capital Management LLC raised its holdings in Lantheus by 595.3% during the first quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider’s stock worth $92,316,000 after acquiring an additional 1,269,900 shares in the last quarter. Swedbank AB bought a new stake in Lantheus during the first quarter worth about $26,346,000. Westfield Capital Management Co. LP raised its holdings in Lantheus by 25.3% during the first quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider’s stock worth $121,867,000 after acquiring an additional 394,837 shares in the last quarter. Vanguard Group Inc. raised its holdings in Lantheus by 5.6% during the first quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider’s stock worth $458,271,000 after acquiring an additional 389,828 shares in the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in Lantheus during the second quarter worth about $26,794,000. Institutional investors own 99.06% of the company’s stock.

Insider Transactions at Lantheus

In other Lantheus news, President Paul Blanchfield sold 2,000 shares of the firm’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total transaction of $192,780.00. Following the transaction, the president now owns 98,980 shares in the company, valued at $9,540,682.20. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Lantheus news, Director Gerard Ber sold 15,500 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the transaction, the director now owns 21,221 shares in the company, valued at $2,047,402.08. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, President Paul Blanchfield sold 2,000 shares of the firm’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the transaction, the president now owns 98,980 shares in the company, valued at approximately $9,540,682.20. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts have issued reports on the company. JMP Securities dropped their price objective on Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 1st. B. Riley upped their price objective on Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Leerink Partners upped their price objective on Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a research note on Thursday, July 11th. Redburn Atlantic assumed coverage on Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective on the stock. Finally, Truist Financial dropped their price objective on Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a research note on Thursday, August 1st. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $126.00.

Lantheus Price Performance

Shares of NASDAQ LNTH opened at $107.98 on Friday. The firm has a market cap of $7.50 billion, a P/E ratio of 17.70 and a beta of 0.51. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $126.89. The business’s 50 day moving average is $108.13 and its 200-day moving average is $94.63.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). The firm had revenue of $394.10 million for the quarter, compared to the consensus estimate of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. Lantheus’s revenue for the quarter was up 22.5% on a year-over-year basis. During the same quarter last year, the business posted $1.40 EPS. Equities research analysts predict that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.